Becton Dickinson and Company (NYSE:BDX) will release earnings for its first quarter before the opening bell on Monday, Feb. 9.Analysts expect the company to report quarterly earnings of $2.81 per share. That’s down from $3.43 per share in the year-ago period. The consensus estimate for Becton Dickinson's quarterly revenue is $5.15 billion (it reported $5.17 billion last year), according to Benzinga Pro.According to recent news, Becton Dickinson announced on Jan. 27 a buyback plan of up to 10 million shares. ...

Becton Dickinson and Company (NYSE:BDX) will release earnings for its first quarter before the opening bell on Monday, Feb. 9.Analysts expect the company to report quarterly earnings of $2.81 per share. That’s down from $3.43 per share in the year-ago period. The consensus estimate for Becton Dickinson's quarterly revenue is $5.15 billion (it reported $5.17 billion last year), according to Benzinga Pro.According to recent news, Becton Dickinson announced on Jan. 27 a buyback plan of up to 10 million shares. ...

Austin, United States, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Surgical Staplers Market Size & Growth Analysis: According to SNS Insider, The Surgical Staplers Market was valued at USD 6.41 billion in 2025 and is projected to reach USD 10.87 billion by 2033, growing at a CAGR of 6.87% during the forecast period 2026-2033. The global burden of chronic diseases that require surgical intervention, rising surgical procedure volumes, and the growing acceptance of minimally invasive and laparoscopic surgeries are all f ...

Market Analysis by covering: Becton Dickinson and Co, Stepan Company, H2O America. Read 's Market Analysis on Investing.com ...

Wall Street analysts expect Becton Dickinson (BDX) to post quarterly earnings of $2.82 per share in its upcoming report, which indicates a year-over-year decline of 17.8%. Revenues are expected to be $5.15 billion, down 0.4% from the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.8% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earn ...

Becton, Dickinson and Company (NYSE:BDX) is included among the Dividend Growth Stocks: 25 Aristocrats. Piper Sandler Highlights Upcoming Segment Transition at Becton Dickinson (BDX) On January 28, Piper Sandler analyst Jason Bednar lifted Becton, Dickinson and Company (NYSE:BDX)’s price recommendation to $205 from $190. The analyst maintained a Neutral rating. The firm pointed to changes in how BD reports its business units starting in Q1 2026 and said it is updating its financial model to align with the ...

Key Takeaways BD completed a joint feasibility study proving polystyrene Petri dishes are a recyclable feedstock.The Pilot used Envetec's GENERATIONS technology to disinfect waste into polymer flakes.The effort supports circular economy goals despite no expected near-term revenue impact.Becton, Dickinson and Company (BDX) , popularly known as BD, recently announced the successful completion of a joint feasibility study evaluating the recycling of polystyrene Petri dishes into high-quality manufacturing feed ...

In this article, we will take a look at the 25 best dividend aristocrat stocks.Dividend aristocrats are companies that have raised their dividends every year for at least 25 years. Investors tend to favor them because a long record of dividend growth creates confidence that payouts can keep rising over time.These companies are usually mature businesses with steady earnings. In many cases, management teams place dividends high on the capital structure, treating regular increases as a core responsibility. For ...

Core Insights - BD reported record revenue of $21.8 billion for fiscal 2025, reflecting a 7.7% growth on an adjusted foreign exchange-neutral basis and 2.9% organic growth, with management highlighting solid performance across key platforms in a dynamic market environment [1][5] - The company described fiscal 2025 as the culmination of its BD 2025 strategy and the beginning of a new growth phase, emphasizing the most prolific growth period in its 128-year history with over $5.4 billion in organic revenue added [1][7] - BD plans to close the combination of its Biosciences and Diagnostic Solutions business with Waters Corp. on February 9, allocating at least half of the expected $4 billion in cash proceeds to share repurchases and the remainder to debt repayment [4][13] Financial Performance - BD achieved a record adjusted operating margin of 25% and reported a 9.6% growth in adjusted diluted EPS, alongside returning $2.2 billion to shareholders, marking its 54th consecutive dividend increase [5][6][10] - The company launched over 125 new products and generated $1.3 billion through more than 20 tuck-in acquisitions while divesting non-strategic assets [8][10] Annual Meeting Outcomes - Shareholders approved all four proposals at the annual meeting, including the election of directors and the ratification of Ernst & Young as the independent auditor for fiscal 2026, with significant support for each proposal [3][15] - The advisory "Say on Pay" vote on executive compensation received approximately 91% support, and the amendment to the 2004 Equity Compensation Plan received 96% support [15] Strategic Initiatives - BD's management highlighted the BD Excellence operating system's contribution to profit and loss leverage, achieving record service levels and consumables quality while navigating macro challenges [6][10] - The company outlined an enhanced capital allocation framework focused on share repurchases, reliable and increasing dividends, and targeted high-growth market acquisitions [14]

作者：情报员 国家知识产权局信息显示，贝克顿·迪金森公司取得一项名为"防止提取粒子遗留的磁体组件"的专利， 授权公告号CN114585444B，申请日期为2020年12月。 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 本文源自：市场资讯 ...